148 related articles for article (PubMed ID: 31833634)
1. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
Brondfield MN; Dodge JL; Hirose R; Heimbach J; Yao FY; Mehta N
Liver Transpl; 2020 May; 26(5):662-672. PubMed ID: 31833634
[TBL] [Abstract][Full Text] [Related]
2. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
3. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
[TBL] [Abstract][Full Text] [Related]
6. Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.
Saberi B; Gurakar A; Tamim H; Schneider CV; Sims OT; Bonder A; Fricker Z; Alqahtani SA
JAMA Netw Open; 2023 Nov; 6(11):e2341096. PubMed ID: 37917059
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
Gutin L; Yao F; Dodge JL; Grab J; Mehta N
JAMA Netw Open; 2019 Aug; 2(8):e1910326. PubMed ID: 31469395
[TBL] [Abstract][Full Text] [Related]
8. HCC Liver Transplantation Wait List Dropout Rates Before and After the Mandated 6-Month Wait Time.
Sokolich J; Buggs J; LaVere M; Robichaux K; Rogers E; Nyce S; Kumar A; Bowers V
Am Surg; 2020 Nov; 86(11):1592-1595. PubMed ID: 32812771
[TBL] [Abstract][Full Text] [Related]
9. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.
Lee E; Sarkar M; Dodge J; Kohi M; Mehta N
Transplantation; 2020 May; 104(5):988-995. PubMed ID: 31577670
[TBL] [Abstract][Full Text] [Related]
10. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
[TBL] [Abstract][Full Text] [Related]
11. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma.
Croome KP; Lee DD; Harnois D; Taner CB
PLoS One; 2017; 12(1):e0170673. PubMed ID: 28122003
[TBL] [Abstract][Full Text] [Related]
13. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
Alver SK; Lorenz DJ; Marvin MR; Brock GN
Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
[TBL] [Abstract][Full Text] [Related]
14. Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.
Goldberg D; French B; Newcomb C; Liu Q; Sahota G; Wallace AE; Forde KA; Lewis JD; Halpern SD
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1638-1646.e2. PubMed ID: 27374003
[TBL] [Abstract][Full Text] [Related]
15. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
16. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
17. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
Am J Transplant; 2019 Aug; 19(8):2210-2218. PubMed ID: 30861298
[TBL] [Abstract][Full Text] [Related]
18. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
19. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
20. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
Mehta N; Sarkar M; Dodge JL; Fidelman N; Roberts JP; Yao FY
Liver Transpl; 2016 Feb; 22(2):178-87. PubMed ID: 26479422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
